Lupin

Long build up is seen in the Lupin Futures, where we have seen 2 per cent rise in the open interest with price rising by 1 per cent

Lupin share price gained after the company announced that it has received tentative approval from the United States Food and Drug Administration (US FDA)

Stocks to Watch, Nov 26: Here is a list of stocks that will be in focus for today's session

Drug firm Lupin is recalling over six lakh bottles of a medication indicated for high blood pressure in the US due to deviation from current good manufacturing practices (CGMP), according to the US health regulator. As per its latest Enforcement Report, US Food and Drug Administration (USFDA), stated that Dr Reddy's Laboratoties is also recalling a product in the US due to a manufacturing issue. Baltimore-based Lupin Pharmaceuticals Inc, a subsidiary of Mumbai-based Lupin, is recalling 6,16,506 bottles of Ramipril capsules in strengths of 2.5 mg, 5 mg and 10 mg, the US health regulator said. The affected lot is manufactured at Lupin's Goa-based manufacturing facility, it stated. The company is recalling 1,12,770 bottles of 2.5 mg tablets; 1,46,322 bottles of 5 mg tablets and 3,57,414 bottles of 10 mg tablets, it said. The US health regulator noted that the company is undertaking Class II voluntary recall due to "CGMP Deviations: Active pharmaceutical ingredient was sourced from an

Stocks to watch, November 8, 2024: Cochin Shipyard reported a Q2FY25 net profit of Rs 193 crore, which is slightly lower than Rs 200 crore in the same period last year

Consolidated net profit of the company, which makes biosimilars and active pharmaceutical ingredients, rose to Rs 853 crore (about $101 million) for the quarter ended Sept. 30

Q2 results today, November 7: Trent, Abbott India, Aditya Birla Fashion and Retail, and more will release their Q2FY25 performance report

Brokerages expect Lupin to report a strong quarter on a year-on-year basis, while a quieter one sequentially

Markets remained volatile and ended slightly lower, taking a breather after Tuesday's decline

Drug firm Lupin on Monday said it has appointed Claus Jepsen as President, Global Specialty business. Jepsen joins Lupin from Takeda Pharmaceuticals, where he led the Global Strategy for rare diseases. "His experience in leading specialty strategy, commercial planning and portfolio choices across key markets will enable us to build our Specialty brand business," Lupin CEO Vinita Gupta said.

Havells witnessed a sharp rally after a breakout from multi-month consolidation phase. However, in line with market corrective phase, the stock retraced towards the neckline of its previous breakout

Lupin share price slipped in trade after the company announced that United States Food and Drug Administration (USFDA) has issued five observations for its Pune-based Biotech facility.

Drug maker Lupin on Monday said it has inked a distribution pact with Ireland-based Scope Ophthalmics to market a product range, indicated for the treatment of various eye conditions, in Mexico. The company has signed a distribution agreement with Scope for the registration and marketing of Moist Heat Mask, a Tea Tree Oil Eyelid Cleansing Gel and Tea Tree Oil Eyelid Wipes of the Optase range in Mexico. The products are used for eye conditions like dry eyes, blepharitis and meibomian gland dysfunction (MGD). "This expansion of our ophthalmology range reinforces our commitment to enhancing vision care for our patients, improving their quality of life," said Fabrice Egros, President Corporate Development and Growth Markets, Lupin. Through the signature of this collaboration with Lupin, Scope is expanding its footprint in Latin America, Scope CEO Tom Freyne stated. "Mexico is clearly a country of strategic importance for SCOPE where our innovative eyecare products, together with the

Lupin share price fell after the United States Food and Drug Administration (USFDA) issued 3 observations for its Pithampur Unit-1, based in Madhya Pradesh.

As per UBS, the Indian pharma market is slowing down due to a sharp increase in unbranded generics

Lupin shares have yielded a return of 74.72 per cent year-to-date, while the Sensex, on the other hand, has advanced 13.72 per cent in 2024

Dr Reddy's Laboratories and Lupin are recalling products in the US due to manufacturing issues, as per the US Food and Drug Administration (USFDA). Dr Reddy's Laboratories Inc, a subsidiary of Hyderabad-based drug firm, is recalling Ibuprofen tablets in multiple strengths, the US health regulator said in its latest enforcement report. Ibuprofen tablets are indicated for pain relief and fever. New Jersey-based Dr Reddy's Laboratories Inc. is recalling 1,03,298 bottles (800 mg); 31,802 bottles (600 mg); and 14,940 bottles (400 mg) of Ibuprofen tablets in the US market, USFDA said. The company is recalling the affected lot due to "Failed impurities/degradation specifications," it added. "Results for unknown impurity were 0.13 per cent and 0.11 per cent, respectively, exceeding the 0.10 per cent specification limit," USFDA noted. The company initiated the Class II nationwide recall on August 6 this year. USFDA stated that Lupin is recalling 4,554 bottles of Cefixime for Oral Suspen

Lupin stock has breached its previous ATH price of 10 years on the monthly chart with massive buying volumes which suggests very bullish sentiment.

Lupin share price today: Lupin set to become the seventh pharmaceutical company to achieve Rs 1-trillion market capitalisation feat

Granules, MCX, Colgate, Trent, Dr.Reddy's, Glenmark Pharma, Voltas, Lupin, Tech Mahindra, Coromandel International and Balrampur Chini among F&O stocks are holding a PCR in excess of 1, shows F&O data